BioAlta, Pfizer Mix And Match In ADC Deal

Pfizer and BioAlta are looking to push the envelope on targeted antibodies, signing an agreement that gives both companies access to the other's technology.

The companies announced Dec. 7 that they will team up to develop and commercialize BioAlta's conditionally active biologic (CAB) antibody...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anticancer

More from Therapeutic Category